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ABSTRACT 1 
Polyphenols may play a chemopreventive role in colorectal cancer (CRC); 2 
however, epidemiological evidence supporting a role for intake of individual 3 
polyphenol classes, other than flavonoids is insufficient. We evaluated the 4 
association between dietary intakes of total and individual classes and 5 
subclasses of polyphenols and CRC risk and its main subsites, colon and 6 
rectum, within the European Prospective Investigation into Cancer and Nutrition 7 
(EPIC) study. The cohort included 476,160 men and women from 10 European 8 
countries. During a mean follow-up of 14 years, there were 5,991 incident CRC 9 
cases, of which 3,897 were in the colon and 2,094 were in the rectum. 10 
Polyphenol intake was estimated using validated centre/country specific dietary 11 
questionnaires and the Phenol-Explorer database. In multivariable-adjusted Cox 12 
regression models, a doubling in total dietary polyphenol intake was not 13 
associated with CRC risk in women (HRlog2 = 1.06, 95 % CI 0.99-1.14) or in 14 
men (HRlog2 = 0.97, 95 % CI 0.90-1.05), respectively. Phenolic acid intake, 15 
highly correlated with coffee consumption, was inversely associated with colon 16 
cancer in men (HRlog2 = 0.91, 95 % CI 0.85-0.97) and positively associated with 17 
rectal cancer in women (HRlog2 = 1.10, 95 % CI 1.02-1.19); although 18 
associations did not exceed the Bonferroni threshold for significance. Intake of 19 
other polyphenol classes was not related to colorectal, colon or rectal cancer 20 
risks. Our study suggests a possible inverse association between phenolic acid 21 
intake and colon cancer risk in men and positive with rectal cancer risk in 22 
women. 23 
24 
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INTRODUCTION 25 
Colorectal cancer (CRC) is the third most common cancer and the fourth most 26 
common cause of death from cancer worldwide, with 1.4 million new cases and 27 
694,000 deaths in 2012 (1). Lifestyle (physical inactivity, body fatness, tobacco 28 
smoking and alcohol consumption) and dietary factors, such as a high intake of 29 
red and processed meat and low intake of fruit and vegetables, are known to 30 
increase CRC risk (2). 31 
Polyphenols are bioactive compounds naturally contained in plant-based foods, 32 
such as tea, coffee, wine, fruit, vegetables, whole-grain cereals, and cocoa (3). 33 
Experimental studies have shown anti-carcinogenic properties of polyphenols 34 
against CRC through several plausible biological mechanisms including 35 
modulation of nuclear factor (NF)-κB genes involved in inflammation and 36 
carcinogenesis, reduction of oxidative damage to lipids and DNA, induction of 37 
phase I and II enzymes, inhibition of angiogenesis, stimulation of DNA repair 38 
and apoptosis (4-7). Based on their chemical backbone, polyphenols are 39 
divided into 4 main classes: flavonoids, phenolic acids, lignans, and stilbenes 40 
(3). Polyphenols can be absorbed in the small intestine, although the vast 41 
majority, from 50 to 99% depending on the polyphenol, transit down to the colon 42 
where they can be metabolized by the gut microbiota and partially absorbed in 43 
the con as small phenolic acids (8). Furthermore, polyphenols can modulate gut 44 
microbiota, both in quantity and type of species (9). Imbalanced gut microbiota, 45 
called dysbiosis, can alter both metabolism and absorption of polyphenols, and 46 
may also induce aberrant molecular signalling, triggering the CRC pathogenesis 47 
(10).  48 
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To date, several case-control studies suggest an inverse association between 49 
flavonoid and lignan intake and CRC risk (3). However, no association in cohort 50 
studies has been observed so far (3;11;12) including our previous results in the 51 
European Prospective Investigation into Cancer and Nutrition (EPIC) study with 52 
a shorter follow-up (13); except for the Iowa Women’s Health study, in which an 53 
inverse association between flavanol intake and rectal cancer risk was shown 54 
(14). To our knowledge, there is only one case-control study investigating the 55 
relationships with other polyphenol classes, such as phenolic acids, stilbenes 56 
and other minor subclasses in Japan (15). In this previous study, intakes of 57 
coffee polyphenols and consequently coffee consumption were inversely 58 
associated with CRC risk in men and women, especially with colon cancer (15). 59 
The Phenol-Explorer (www.phenol-explorer.eu) (16), a food composition 60 
database on all known dietary polyphenols, greatly facilitates the assessment of 61 
relationships between polyphenol intake and chronic disease risk. The aim of 62 
the present study was to investigate the associations between the intake of total 63 
polyphenols and individual polyphenol subclasses and CRC risk and by subsite 64 
(colon and rectum) in the EPIC study, a large cohort with a high variability in 65 
polyphenol intake and a long follow-up (17). 66 
MATERIALS AND METHODS 67 
Subjects and study design 68 
EPIC is an on-going cohort consisting of 521,324 adult participants, mostly 69 
recruited from the general population, enrolled between 1992 and 2000 from 23 70 
centres in 10 European countries: Denmark, France, Germany, Greece, Italy, 71 
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the Netherlands, Norway, Spain, Sweden and the United Kingdom (18). All 72 
participants gave written informed consent, and the study was approved by the 73 
local ethics committees in the participating countries and the ethical review 74 
board of the International Agency for Research on Cancer (IARC). We excluded 75 
participants with prevalent cancer other than non-melanoma skin cancer at 76 
baseline or with missing information on date of diagnosis or incomplete follow-77 
up data (n=29,332), missing data on dietary or lifestyle factors (n=6,259), 78 
extreme energy intake and/or expenditure (participant in the top or the bottom 79 
1% of the distribution of the ratio of total energy intake to energy requirement; 80 
n=9,573). In the current analysis, 476,160 men and women were included. 81 
Identification and follow-up of colorectal cancer cases 82 
Cancer cases were identified through population cancer registries in Denmark, 83 
Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom. In 84 
France, Germany, Greece and Naples-Italy, a combination of methods was 85 
used including health insurance records, cancer and pathology registries, and 86 
by active follow-up of study participants and their next of kin. Vital status was 87 
collected from regional or national mortality registries.  88 
Cancer incidence data were coded according to the 10th revision of the 89 
International Statistical Classification of Diseases, Injuries and Causes of Death 90 
(ICD-10) and the second revision of the International Classification of Diseases 91 
for Oncology (ICDO-2). Proximal colon cancers included those within the 92 
cecum, appendix, ascending colon, hepatic flexure, transverse colon, and 93 
splenic flexure (C18.0–18.5). Distal colon cancers included those within the 94 
descending (C18.6) and sigmoid (C18.7) colon. Overlapping (C18.8) and 95 
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unspecified (C18.9) lesions of the colon were grouped among all colon cancers 96 
only (C18.0-C18.9). Cancer of the rectum included tumours occurring at the 97 
recto sigmoid junction (C19) and rectum (C20). Five hundred and fourteen 98 
cases were censored because they were carcinoma in situ (n=193), non-99 
adenocarcinoma, mixed types or not well defined (n=312), unknown histology of 100 
the cancer (n=5), or a CRC originating from other organs (n=4). 101 
Dietary assessment and data collection 102 
At recruitment, validated country/centre-specific dietary questionnaires were 103 
used for recording habitual diet over the previous 12 months (18;19). Most 104 
centres utilized a self-administered food frequency questionnaire. In the 105 
remaining centres (Greece, Spain, and Ragusa and Naples-Italy), a face-to-face 106 
diet history questionnaire was employed to collect dietary information. In 107 
Malmö-Sweden, a method combining a food frequency questionnaire with a 7-108 
day dietary diary and 1h interview was used. Total energy, alcohol, and nutrient 109 
intakes were estimated by using the standardized EPIC Nutrient Database (20). 110 
Lifestyle questionnaires were collected to obtain information on lifetime and 111 
smoking status, physical activity classified according to the Cambridge Physical 112 
Activity Index (21), education, menstrual and reproductive history. Height and 113 
weight were measured at baseline in all centres except for Norway, France, and 114 
the majority of participants in EPIC-Oxford where anthropometric measures 115 
were self-reported (18). 116 
Polyphenol intake 117 
12 
 
Dietary polyphenol intake was estimated using the Phenol-Explorer database 118 
(16) accounting for cooking and processing of foods via retention factors (22), 119 
as previously described (17;23). Total polyphenols was calculated as the sum of 120 
all classes of polyphenols: flavonoids [anthocyanidins, chalcones, 121 
dihydrochalcones, dihydroflavonols, flavanols (including flavan-3-ol monomers, 122 
proanthocyanidins, theaflavins), flavanones, flavones, flavonols, and 123 
isoflavones], phenolic acids (hydroxybenzoic acids, hydroxycinnamic acids, and 124 
hydroxyphenylacetic acids), lignans, stilbenes, and other minor polyphenols 125 
(alkylphenols, tyrosols, alkymethoxyphenols, furanocoumarins, 126 
hydroxybenzaldehydes, and hydroxycoumarins). The content of polyphenols 127 
was expressed in mg/100 g of food fresh weight. 128 
Statistical analysis 129 
Polyphenol intakes were analysed as categorical variables based on quintiles of 130 
the distribution among the entire EPIC cohort and by sex. Tests for linear trend 131 
were performed by assigning the medians of each quintile as scores. 132 
Polyphenol intakes were also analysed as continuous variables, after log2 133 
transformation to improve normality of intake distributions. Each increase of one 134 
unit corresponded to a doubling in intake.  135 
Multivariable Cox proportional hazard models were used to calculate hazard 136 
ratios (HR) and 95% confidence intervals (CIs) of the associations between 137 
total, classes and subclasses of polyphenol intakes and CRC risk. A chi-138 
squared test based upon the scaled Schoenfeld residuals was used to ensure 139 
that the assumptions of proportional hazards were met. Age was the primary 140 
time variable in all models. Entry time was age at recruitment and exit time was 141 
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age at diagnosis, death or censoring date (lost or end of follow-up), whichever 142 
came first. Model 1 was stratified by centre (to control for differences in 143 
questionnaires, follow-up procedures) and age at baseline (1-y interval). Model 144 
2 was additionally adjusted for non-dietary variables: smoking status and 145 
intensity (never, former quit <11 years, former quit 11–20 years, former quit >20 146 
years, current <16 cigarettes/d, current 16–25 cigarettes/d, current >25 147 
cigarettes/d, current occasional, and not specified), physical activity (inactive, 148 
moderately inactive, moderately active, active, and not specified), education 149 
level (none, primary school, technical/professional school, secondary school, 150 
university or higher, and not specified), and body mass index (BMI, continuous 151 
kg/m2); and in women also for menopausal status (pre-, peri-, post-menopausal, 152 
surgical menopause), hormone replacement therapy use (yes, no, and 153 
unknown), and oral contraceptive use (yes, no, and unknown). Model 3 was 154 
further adjusted for dietary variables: total energy intake (kJ/d), alcohol (g/d), 155 
red and processed meat (g/d), fibre (g/d) and calcium (mg/d) intakes. The 156 
multivariable model for phenolic acids was additionally adjusted for coffee 157 
intake, because coffee is its main food source by far (17). Moreover, model 1 158 
and 2 were also adjusted for total energy intake to assess the effect of absolute 159 
versus relative intakes of polyphenols in the diet. Results of Cox models with 160 
and without adjusting for total energy intake were almost identical. Furthermore, 161 
polyphenol intakes were also included in the statistical models as nutrient 162 
density (mg/8240kJ day) (24). This energy-adjustment method did not modify 163 
the results appreciably. 164 
Interactions between polyphenol intakes (continuous as mg/day) and sex, age 165 
(<55 years, 55 to 65 years, or >65 years), BMI (BMI<25, 25 to <30, ≥30 kg/m2), 166 
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tobacco smoking status (never, former, current smokers) and alcohol 167 
consumption (for women <15g/d and ≥15g/d; and for men <30g/d and ≥30g/d) 168 
were evaluated in separate analyses. The statistical significance of interactions 169 
on the multiplicative scale was assessed using the likelihood ratio test. 170 
Separate sex-specific models were fitted because a statistically significant 171 
interaction between sex and intake of total polyphenols was detected. In 172 
addition, we assessed separate models by smoking status category because a 173 
statistically significant interaction with smoking status (never, former, and 174 
current smokers) was observed. The Wald test statistic was used to evaluate 175 
heterogeneity by anatomical subsites of CRC (colon, proximal colon, distal 176 
colon, and rectum). Additional analyses by length of follow-up [censoring data at 177 
3-, 6-, 9-, 12-, 15-, 18-years, and maximum of follow-up (22.8 years)] were 178 
performed. Sensitivity analyses were performed by repeating main analyses 179 
after the exclusion of 462 CRC cases diagnosed during the first 2 years of 180 
follow-up (279 colon and 183 rectum cancer cases). All P values presented are 181 
2-tailed and were considered to be statistically significant when P <0.05. To 182 
account for multiple testing for the subclasses of polyphenols, Bonferroni 183 
correction was used and then results were considered statistically significant if 184 
P<0.05/26 (number of tests for the intakes of all polyphenol subclasses) <0.002. 185 
All statistical analyses were conducted using R 3.2.1 software (R Foundation for 186 
Statistical Computing, Vienna, Austria). 187 
RESULTS 188 
During 13.9 (4.0) years of mean (SD) follow-up, 5,991 (56.8% in women) 189 
incident primary CRC cases were diagnosed, of which 3,897 were identified as 190 
colon cancers (including 1,877 proximal, 1,743 distal, and 277 overlapping or 191 
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unspecified colon cancers) and 2,094 as rectum cancers. The number of 192 
participants and distribution of CRC cases by country and sex are presented in 193 
Table 1. The highest estimated median of total polyphenol intakes among both 194 
sexes were in Denmark; whereas the lowest intakes amongst women and men 195 
were observed in Norway and Spain, respectively (Table 1). Phenolic acids 196 
were the main contributors to total polyphenols (51.0%), followed by flavonoids 197 
(44.2%), other minor polyphenol classes (4.4%), lignans (0.2%) and stilbenes 198 
(0.2%). Baseline characteristics of study participants by quintile of total 199 
polyphenol intake are shown in Supplementary Table 1. Men and women in 200 
the higher polyphenol intake groups were older, more physically active, had a 201 
lower BMI, higher educational level, and had a lower proportion of never 202 
smokers. Higher total polyphenol intake was also associated with higher 203 
average intakes of total energy, alcohol, calcium, fibre and red meat compared 204 
to participants with lower total polyphenol intakes. Furthermore, women with 205 
higher total polyphenol intakes were more likely to be post-menopausal and 206 
users of hormone replacement therapy and oral contraceptives than those with 207 
lower total polyphenol intakes. 208 
In multivariable models, total polyphenol intake was not associated with CRC 209 
risk in either women (HRlog2 = 1.06, 95 % CI 0.99 - 1.14) or men (HRlog2 = 0.97, 210 
95 % CI 0.90 - 1.05) (Psex-interaction < 0.001) (Table 2). Null associations were 211 
also observed with the risk of colon cancer and its anatomical subsites 212 
(proximal and distal) in women; although a borderline statistically significant 213 
inverse association was observed in men for colon cancer, especially for 214 
proximal cancer (HRlog2 = 0.85, 95 % CI 0.73 – 0.99). Higher intakes of total 215 
polyphenols were significantly associated with a higher rectal cancer in women 216 
16 
 
(HRlog2 = 1.25, 95 % CI 1.10 - 1.41) but not in men (HRlog2 = 1.08, 95 % CI 0.95 - 217 
1.23) (Psex-interaction = 0.026). 218 
For CRC, no statistically significant relationships were observed between any of 219 
the classes and subclasses of polyphenols neither in women nor in men (Table 220 
3). For colon cancers, inverse associations with the intake of total phenolic 221 
acids (HRlog2 = 0.91, 95 % CI 0.85 - 0.97; P=0.005) (Psex-interaction < 0.001) and its 222 
main subclass hydroxycinnamic acids (HRlog2 = 0.92, 95 % CI 0.87 - 0.97; 223 
P=0.004), as well as for methoxyphenols (HRlog2 = 0.99, 95 % CI 0.98 – 1.00; 224 
P=0.007) were found only in men. For rectal cancers, positive associations 225 
were observed in women with the intake of phenolic acids (HRlog2 = 1.10, 95 % 226 
CI 1.02 - 1.19; P=0.013) (Psex-interaction = 0.22), and its subclasses 227 
hydroxybenzoic acids (HRlog2 = 1.05, 95 % CI 1.00 - 1.10; P=0.039), and 228 
hydroxycinnamic acids (HRlog2 = 1.07, 95 % CI 1.00 - 1.15; P=0.038), as well as 229 
for flavanones (HRlog2 = 1.03, 95 % CI 1.00 - 1.07; P=0.048), 230 
alkylmethoxyphenols (HRlog2 = 1.04, 95 % CI 1.00 - 1.08; P=0.031), and 231 
methoxyphenols (HRlog2 = 1.02, 95 % CI 1.00 - 1.03; P=0.036). In women, a 232 
significant positive association was also detected between the risk of rectal 233 
cancer and flavonoid intake using the continuous variable (HRlog2 = 1.09, 95 % 234 
CI 1.00 - 1.18; P=0.039), but not using the quintiles (HRQ5 vs Q1 = 1.23, 95 % CI 235 
0.94 - 1.60; P-trend=0.41). In men, an inverse association was found between 236 
hydroxybenzaldehyde intake and rectal cancer (HRlog2 = 0.97, 95 % CI 0.95 – 237 
1.00; P=0.035). However, none of these associations exceeded the Bonferroni 238 
significance threshold. 239 
There were no evidence that age, BMI, and baseline alcohol intake modified the 240 
association between total polyphenol intake and CRC risk in the multivariable 241 
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models. Since a statistically significant interaction between smoking status 242 
(never, former, and current smoker) and total polyphenol (Pinteraction = 0.033) and 243 
flavonoid (Pinteraction = 0.037) intake in relation to CRC risk was observed in 244 
women, we stratified the statistical models by smoking status (Supplementary 245 
table 2). In most of cases, stronger associations were detected in either never 246 
or current smokers, although the results obtained were similar to those of the 247 
entire cohort. 248 
In additional analysis, the relationships between the intake of total polyphenols 249 
and their main classes (flavonoids and phenolic acids) and the risk of overall 250 
CRC and by anatomical subsite (colon and rectal cancers) (Figure 1) were 251 
performed by length of follow-up [at 3 years, 6 years, 9 years, 12 years, 15 252 
years, 18 years, and maximum of follow-up (22.8 years)]. When censoring data 253 
at 3 years of follow-up, no associations were observed. At 6 years, all 254 
associations were similar to those found after the longest follow-up, although 255 
not all of them were statistically significant. The strongest results were found 256 
censoring data at 9 years of follow-up, while in longer follow-ups (>9 years) the 257 
associations were progressively attenuated. 258 
In a separate sensitivity analysis in which the 462 CRC cases diagnosed within 259 
the first 2 years of follow-up were excluded, the associations between the intake 260 
of total polyphenols and polyphenol classes and overall CRC risk and by 261 
anatomical subsite were practically identical to results based on the whole 262 
cohort (data not shown). 263 
DISCUSSION 264 
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In the present European prospective multi-country study, no statistically 265 
significant association between total polyphenol intake and overall CRC risk 266 
was observed. This is in line with findings of the Fukuoka colorectal case-267 
control study (15). However, we observed a suggestive inverse association 268 
between total polyphenols intake and colon cancer risk in men and a positive 269 
one with rectal cancer risk in women. These findings for total polyphenol intake 270 
were almost identical to those found for phenolic acid intake. 271 
Phenolic acids are the main contributors to total polyphenol intake (49.0% and 272 
54.7% in Mediterranean and non-Mediterranean EPIC countries, respectively) 273 
and coffee is, by far, their principal food source (70.6-74.6%) (17). In the current 274 
study, we did not see an association between phenolic acid intake and CRC risk 275 
in either men or women. Similar results were also observed after adjustment for 276 
coffee intake, implying that other food sources of phenolic acids were not 277 
related to CRC risk. In a nested case-control study within EPIC, no associations 278 
were found between concentrations of phenolic acids in plasma (including 279 
caffeic and ferulic acids which are major phenolic acids associated with coffee 280 
intake) (25) and colon cancer risk, except that homovanillic acid was associated 281 
with an increased risk (26). Plasma homovanillic acid is most probably 282 
associated with the metabolism of catecholamines and cannot be directly linked 283 
to phenolic acid intake. In the Fukuoka colorectal case-control study a 284 
borderline statistically significant inverse association between coffee polyphenol 285 
intake (which accounts for most phenolic acids) and colon cancer risk was 286 
reported in both sexes, but not for rectal cancer risk (15). In the EPIC study, null 287 
results were previously shown between coffee intake and overall CRC risk (27) 288 
and CRC mortality (28), although inverse associations with colon cancer risk in 289 
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men and positive associations with rectal cancer risk in women (27) and CRC 290 
mortality in women (28) were noted. In two recent meta-analyses, coffee intake 291 
was not associated with the risk of both overall CRC and rectum cancers in 292 
cohort studies (29;30); although higher doses of coffee (>5cups/day) has been 293 
reported to decrease the risk of colon cancer (30). However, the evidence is 294 
inconsistent; in an Australian-based case-control study, iced coffee 295 
consumption was associated with a higher risk of rectal cancer (31). 296 
Interestingly, in a recent meta-analysis of coffee intake, including 8 Japanese 297 
cohorts, a significant decreased risk of colon cancer was observed in women, 298 
but not in men (32). Moreover, no association was observed with rectal cancer 299 
risk in both sexes; although a significant increase was detected after excluding 300 
cases diagnosed within 3 years of the baseline only in women. Despite the 301 
suggestive epidemiological evidence regarding sex and anatomical location, 302 
there is heterogeneity in the association between phenolic acid and coffee in 303 
relation to CRC, thus further research is needed to confirm these results and to 304 
elucidate the underlying mechanisms of action. Part of these discrepancies 305 
might be because different types of coffee have different polyphenol 306 
compositions and contents, which are difficult to take into account in large 307 
epidemiological studies, such as in EPIC (33). In an Israeli-based case-control 308 
study, a significant inverse association was found between CRC risk and the 309 
intake of boiled and expresso coffees but not instant and filter coffees, with 310 
stronger associations for colon cancer (34). Phenolic acid intake is highly 311 
correlated with coffee intake (35) and therefore, other coffee constituents such 312 
as caffeine, cafestol and kahweol may also contribute to any association with 313 
CRC risk (36). No associations between total, caffeinated or decaffeinated 314 
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coffee and CRC risk were found in the Prostate, Lung, Colorectal, and Ovarian 315 
Cancer Screening Trial (37). Indeed, CYP1A2 and NAT2 genotypes, enzymes 316 
involved in caffeine metabolism, did not affect associations between coffee 317 
consumption and CRC risk (27). Therefore, caffeine does not seem to play a 318 
role in CRC pathogenesis. Another potential explanation for these differences in 319 
the relationships between cancer sites and sexes is due to endogenous factors, 320 
such as metabolic heterogeneity and gut microbiota, which may influences 321 
coffee bioavailability and therefore the bioactivity and bioefficacy of its 322 
constituents. Gut microbiota composition slightly varies between sexes (38), 323 
and especially, depend on the interaction between sex and diet (39). 324 
We did not observe clear associations between flavonoid intake, the second 325 
major contributor to total polyphenols (44.3%), and CRC risk, and anatomical 326 
subsites in both men and women. These results were in concordance with our 327 
previous study with shorter follow-up (13), and three meta-analyses of 328 
prospective studies (40-42), although some protective associations have been 329 
systematically reported in case-control studies (41;42). In these prospective 330 
studies and in agreement with the present findings, no association was 331 
observed either with any of the flavonoid subclasses. However, some inverse 332 
associations have been reported between CRC risk and specific flavonoid 333 
compounds such as tea polyphenols and isoflavones. Urinary biomarkers of 334 
green tea polyphenols were also associated with a reduced risk of developing 335 
colon cancer in Chinese men (43); however, in Europe black tea is the type 336 
usually consumed. Plasma equol concentration, but not other isoflavones, was 337 
inversely related to colon cancer risk in a previous nested case-control study 338 
within EPIC (26). In contrast, no association was found with plasma and urinary 339 
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isoflavone levels in the EPIC-Norfolk study (44) or with dietary isoflavone 340 
intakes in a meta-analysis of cohort studies (11). 341 
No association between lignan intake and CRC risk was observed in our study, 342 
as previously reported in a meta-analysis of cohort studies. No association was 343 
found with urinary and plasma lignan concentrations in EPIC (26;44) and in a 344 
Dutch cohort (45). However an inverse association between intakes of dietary 345 
enterolignan and enterodiol and CRC risk were found in women but not in men 346 
from EPIC-Norfolk (44). 347 
No significant association between any minor subclasses of polyphenols and 348 
CRC risk was observed in our study. Methoxyphenols (guaiacol is the only 349 
polyphenol in this class) showed a similar pattern of associations to phenolic 350 
acids, because the main food source is coffee (17). In agreement with present 351 
observations, plasma concentrations of stilbenes and tyrosols were not related 352 
to colon cancer (26), although an inverse association between plasma 353 
alkylresorcinols, biomarkers of whole-grain wheat and rye intake, and distal 354 
colon cancer risk (46) was observed in a previous nested case-control study 355 
within EPIC. 356 
We also investigated the relationships between polyphenol intake and CRC risk 357 
over the years of follow-up. The strongest associations were found from 6 to 9 358 
years of follow-up, which may be the presumable period of progression from 359 
asymptomatic precancerous polyps to CRC (47;48). Results from longer follow-360 
ups tended to be attenuated, which could be due to misclassification bias. The 361 
longer the follow-up the higher the chance of change of dietary and lifestyle 362 
habits by the participants. This can be evaluated with periodic reassessments of 363 
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the main exposure and the cofounders. Despite this attenuation, our findings 364 
after a mean of 14 years of follow-up maintained their significance because 365 
accrual of more cases meant there was greater statistical power to detect 366 
associations.  367 
The major strengths of the present study are its prospective design, its long 368 
follow-up, its large size and number of cases, and the coverage of several 369 
European countries with large dietary heterogeneity. This study also has 370 
several potential limitations. First, diet and other lifestyle variables were only 371 
available at baseline, and therefore, changes in these variables could not be 372 
taken into account in these analyses. The second limitation may be the 373 
measurement error in collecting dietary intake, but centre/country-specific 374 
validated questionnaires for polyphenol-rich foods were used (19). Moreover, 375 
the Phenol-Explorer is the most comprehensive food composition database on 376 
polyphenols available nowadays (16). The third limitation is the potential 377 
modification of diet during the early prediagnostic period of the disease; 378 
however, sensitivity analyses excluding incident cases diagnosed in the first 2 379 
years of follow-up did not alter the associations. The fourth limitation is the 380 
potential impact of residual confounding, since several lifestyle and other dietary 381 
factors related to CRC were different according to polyphenol intake. Although 382 
we have included them in the statistical models, measurement error and 383 
changes during follow-up may affect our results. Finally, we realize that our 384 
study is prone to the well-known drawback of multiple comparisons. We have 385 
therefore applied the Bonferroni correction and none of the tested associations 386 
remained statistically significant. Despite this rather conservative method, we 387 
were still able to observe borderline statistically significant associations. 388 
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In summary, we found that higher intakes of phenolic acids, reflecting high 389 
coffee consumption, were associated with a lower risk of colon cancer in men 390 
and a higher risk of rectal cancer in women, although the findings were no 391 
longer significant after Bonferroni correction. Further studies are warranted to 392 
evaluate the potential role of the intakes of phenolic acids and coffee in CRC 393 
development. 394 
  395 
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 Figure 1. Hazard ratios and (95% CI) for colorectal cancer and subsites by sex 
and length of follow-up, according to double the intake (log2) of total polyphenol, 
flavonoid, and phenolic acid in women (black circles) and men (grey circles) 
from the EPIC study. 
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Table 1. Distribution of subjects and colorectal cancer cases according to anatomical subsite and medians (5th–95th percentiles) of 
total polyphenol intake in 10 participating countries in the EPIC Study. 
Country 
  Colorectal cancer cases, N Polyphenol 
intake (mg/d) 
Flavonoid 
intake (mg/d) 
Phenolic acid 
intake (mg/d) N Overall Colon Proximal Distal NOS Rectum 
Women 
          Denmark 28,720 533 363 170 161 32 170 1,552 (802-2,481) 514 (133-1,459) 890 (320-1,547) 
France 67,403 410 264 129 125 10 146 1,320 (552-2,603) 514 (188-1,226) 679 (165-1,848) 
Germany 27,379 177 121 66 53 2 56 1,033 (549-1,927) 414 (153-1,051) 504 (194-1,074) 
Greece 15,233 41 25 11 7 7 16 759 (345-1,556) 247 (101-528) 416 (105-1,105) 
Italy 30,513 342 264 119 116 29 78 853 (443-1,438) 413 (175-791) 377 (118-757) 
Norway 33,975 297 195 104 86 5 102 653 (263-1,090) 184 (61-400) 371 (66-844) 
Spain 24,850 218 154 57 79 18 64 671 (254-1,407) 282 (80-684) 311 (61-907) 
Sweden 26,368 442 305 182 108 15 137 838 (418-1,465) 272 (89-678) 488 (166-971) 
The Netherlands 26,912 387 268 154 109 5 119 1,158 (631-1,760) 514 (185-1,008) 574 (186-985) 
United Kingdom 52,566 555 381 216 132 33 174 1,443 (662-2,240) 873 (317-1,495) 469 (129-1,054) 
TOTAL 333,919 3,402 2,340 1,208 976 156 1,062 1,054 (415-2,148) 420 (116-1,239) 508 (123-1,318) 
Men 
          Denmark 26,294 709 395 161 202 32 314 1,594 (809-2,460) 397 (107-1,271) 993 (359-1,629) 
France - - - - - - - - - - 
Germany 21,178 258 141 59 67 15 117 1,093 (554-2,079) 402 (140-1,056) 549 (199-1,226) 
Greece 10,815 51 31 10 10 11 20 967 (469-1,921) 302 (126-614) 538 (153-1,377) 
Italy 14,032 228 160 55 86 19 68 1,009 (522-1,695) 493 (202-964) 428 (156-805) 
Norway - - - - - - - - - - 
Spain 15,139 339 220 81 126 13 119 834 (333-1,725) 425 (118-1,085) 315 (92-769) 
Sweden 22,306 473 284 142 136 6 189 888 (442-1,568) 252 (75-664) 544 (193-1,064) 
Table 1 Click here to download table Table 1.docx 
The Netherlands 9,627 119 58 29 26 3 61 1,155 (601-1,854) 398 (137-910) 674 (178-1,198) 
United Kingdom 22,850 412 268 132 114 22 144 1,509 (735-2,309) 916 (334-1,519) 517 (157-1,076) 
TOTAL 142,241 2,589 1,557 669 767 121 1,032 1,150 (505-2,159) 419 (117-1,246) 562 (162-1,396) 
 
 
Table 2. HRs (95% CIs) for colorectal cancer (CRC) and subsites, according to quintile of intake of total polyphenols in women and 
men from the EPIC study. 
 
Overall CRC Colon Proximal Distal P-
value1 
Rectum P-
value2 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Women         
Model 1 Quintile 1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 
1.00 (ref) 
 
 
Quintile 2 1.00 (0.89-1.13) 0.96 (0.83-1.10) 1.02 (0.84-1.24) 0.86 (0.70-1.06) 
 
1.13 (0.91-1.40) 
 
 
Quintile 3 1.11 (0.99-1.26) 1.02 (0.89-1.18) 1.06 (0.87-1.30) 0.96 (0.77-1.19) 
 
1.37 (1.10-1.71) 
 
 
Quintile 4 1.10 (0.97-1.25) 0.99 (0.85-1.16) 1.14 (0.92-1.41) 0.81 (0.64-1.02) 
 
1.39 (1.10-1.76) 
 
 
Quintile 5 1.12 (0.98-1.28) 0.99 (0.85-1.17) 1.12 (0.89-1.41) 0.85 (0.66-1.09) 
 
1.45 (1.34-1.86) 
 
 
P-trend 0.09 0.93 0.26 0.22 
 
0.004 
 
 
Continuous (log2) 1.06 (0.99-1.13) 0.99 (0.92-1.07) 1.05 (0.94-1.16) 0.92 (0.83-1.03) 0.11 1.22 (1.09-1.37) 0.002 
Model 3 Quintile 1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 
1.00 (ref) 
 
 
Quintile 2 1.00 (0.89-1.13) 0.96 (0.83-1.10) 1.02 (0.84-1.24) 0.86 (0.70-1.07) 
 
1.13 (0.91-1.41) 
 
 
Quintile 3 1.12 (0.99-1.26) 1.02 (0.88-1.18) 1.05 (0.86-1.30) 0.97 (0.78-1.21) 
 
1.39 (1.11-1.74) 
 
 
Quintile 4 1.10 (0.97-1.26) 0.99 (0.85-1.17) 1.13 (0.90-1.41) 0.82 (0.64-1.06) 
 
1.41 (1.10-1.80) 
 
 
Quintile 5 1.13 (0.97-1.30) 1.00 (0.83-1.19) 1.11 (0.86-1.42) 0.87 (0.66-1.14) 
 
1.49 (1.14-1.94) 
 
 
P-trend 0.10 0.92 0.35 0.36 
 
0.006 
 
 
Continuous (log2) 1.06 (0.99-1.14) 0.99 (0.91-1.07) 1.04 (0.93-1.17) 0.93 (0.82-1.06) 0.22 1.25 (1.10-1.41) 0.002 
Men         
Model 1 Quintile 1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 
1.00 (ref) 
 
 
Quintile 2 1.02 (0.90-1.16) 1.08 (0.92-1.27) 0.95 (0.74-1.22) 1.23 (0.98-1.54) 
 
0.92 (0.75-1.13) 
 
 
Quintile 3 0.96 (0.84-1.10) 1.02 (0.86-1.21) 0.94 (0.73-1.20) 1.14 (0.90-1.44) 
 
0.88 (0.71-1.08) 
 
 
Quintile 4 0.94 (0.82-1.08) 0.93 (0.78-1.11) 0.81 (0.62-1.06) 1.07 (0.83-1.37) 
 
0.95 (0.77-1.18) 
 
 
Quintile 5 0.89 (0.77-1.02) 0.82 (0.68-0.99) 0.78 (0.59-1.03) 0.84 (0.64-1.11) 
 
0.97 (0.78-1.22) 
 
 
P-trend 0.05 0.010 0.05 0.07 
 
0.94 
 
  Continuous (log2) 0.94 (0.88-1.01) 0.88 (0.81-0.97) 0.85 (0.74-0.97) 0.91 (0.80-1.04) 0.43 1.05 (0.93-1.17) 0.022 
Table 2 Click here to download table Table 2.docx 
Model 3 Quintile 1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)  1.00 (ref)  
 Quintile 2 1.03 (0.91-1.17) 1.10 (0.93-1.29) 0.95 (0.74-1.22) 1.27 (1.01-1.59)  0.93 (0.75-1.14)  
 Quintile 3 0.97 (0.85-1.11) 1.04 (0.87-1.23) 0.93 (0.72-1.21) 1.18 (0.92-1.51)  0.88 (0.71-1.10)  
 Quintile 4 0.96 (0.83-1.11) 0.95 (0.79-1.15) 0.80 (0.61-1.06) 1.12 (0.86-1.46)  0.96 (0.77-1.21)  
 Quintile 5 0.94 (0.80-1.10) 0.89 (0.72-1.09) 0.79 (0.58-1.08) 0.95 (0.71-1.28)  1.01 (0.79-1.29)  
 P-trend 0.30 0.09 0.10 0.36  0.65  
  Continuous (log2) 0.97 (0.90-1.05) 0.91 (0.82-1.01) 0.85 (0.73-0.99) 0.97 (0.84-1.12) 0.21 1.08 (0.95-1.23) 0.036 
1P-value for heterogeneity for proximal vs distal colon cancer 
2P-value for heterogeneity for colon vs rectum cancer 
Model 1: Cox model was stratified by age and centre. 
Model 3: Cox model was additionally adjusted for smoking status and intensity, physical activity, education level, body mass index, 
total energy intake, alcohol, red and processed meat, fibre (g/d) and calcium (mg/d) intakes and in women also for menopausal 
status, hormone replacement therapy use, and oral contraceptive use.  
 
Table 3. Hazard ratios (95% CIs) for colorectal cancer and subsites, according to double the intake of polyphenol classes and 
subclasses by sex in the EPIC study. 
 
*P-value<0.05; **P-value<0.01; any association exceeds the Bonferroni threshold (P<0.05/26) < 0.002 
1P-value for heterogeneity for colon vs rectum cancer 
2P-value for interaction by sex in colorectal cancer 
Intake (mg/d) Colorectal Colon Rectum Intake (mg/d) Colorectal Colon Rectum
median (P5%-P95%) HR (95% CI) HR (95% CI) HR (95% CI) median (P5%-P95%) HR (95% CI) HR (95% CI) HR (95% CI)
Flavonoid subclasses 419.7 (116.3-1238.9) 1.03 (0.98-1.08) 1.00 (0.95-1.06) 1.09 (1.00-1.18)* 0.10 418.8 (117.4-1245.8) 1.00 (0.96-1.05) 1.00 (0.94-1.06) 1.01 (0.94-1.09) 0.87 0.030
Anthocyanins 25.5 (3.7-116.1) 1.01 (0.99-1.04) 1.00 (0.97-1.03) 1.02 (0.97-1.06) 0.46 22.9 (2.8-120.5) 0.99 (0.97-1.01) 1.00 (0.97-1.02) 0.98 (0.95-1.01) 0.49 0.09
Dihydrochalcones 1.8 (0.1-6.3) 1.00 (0.99-1.02) 1.00 (0.99-1.02) 1.01 (0.98-1.03) 0.76 1.5 (0.1-6.9) 1.00 (0.99-1.01) 0.99 (0.98-1.01) 1.00 (0.98-1.01) 0.61 0.038
Dihydroflavonols 0.4 (0.0-9.6) 1.00 (1.00-1.01) 1.00 (0.99-1.00) 1.00 (0.99-1.01) 0.20 1.0 (0.0-18.4) 0.99 (0.99-1.00) 0.99 (0.99-1.00) 0.99 (0.98-1.00) 0.64 0.027
Flavanols 285.6 (62.4-1015.5) 1.02 (0.98-1.06) 1.00 (0.95-1.04) 1.05 (0.98-1.13) 0.19 283.5 (65.1-1028.8) 1.01 (0.97-1.05) 0.99 (0.94-1.04) 1.01 (0.95-1.08) 0.51 0.043
Flavan-3-ol monomers 39.8 (6.4-460.4) 1.01 (0.99-1.03) 0.99 (0.97-1.02) 1.04 (1.00-1.09) 0.08 42.8 (7.4-466.1) 1.00 (0.97-1.02) 0.99 (0.96-1.02) 1.00 (0.96-1.04) 0.63 0.08
Proanthocyanidins 202.9 (52.4-532.0) 1.04 (0.99-1.08) 1.01 (0.96-1.07) 1.06 (0.98-1.15) 0.29 203.7 (51.5-552.1) 1.00 (0.96-1.05) 0.99 (0.93-1.04) 1.00 (0.93-1.07) 0.56 0.020
Theaflavins 1.6 (0.0-106.4) 1.00 (1.00-1.01) 1.00 (1.00-1.00) 1.01 (1.00-1.01) 0.26 1.5 (0.0-112.0) 1.00 (1.00-1.01) 1.00 (1.00-1.01) 1.00 (1.00-1.01) 0.74 0.06
Flavanones 25.6 (1.8-118.3) 1.00 (0.99-1.02) 0.99 (0.97-1.02) 1.03 (1.00-1.07)* 0.05 24.2 (2.2-120.0) 0.99 (0.97-1.01) 0.99 (0.96-1.01) 1.00 (0.96-1.03) 0.69 0.10
Flavones 9.3 (2.7-26.6) 1.02 (0.98-1.06) 1.02 (0.97-1.07) 1.02 (0.95-1.10) 0.09 9.4 (2.3-30.4) 0.98 (0.94-1.03) 0.96 (0.91-1.02) 0.97 (0.90-1.04) 0.42 0.027
Flavonols 27.9 (6.9-112.0) 1.01 (0.97-1.05) 0.99 (0.94-1.04) 1.07 (0.99-1.15) 0.08 29.5 (7.9-113.3) 1.01 (0.96-1.05) 0.99 (0.94-1.05) 1.00 (0.93-1.07) 0.57 0.23
Isoflavonoids 0.0 (0.0-7.3) 1.01 (1.00-1.02) 1.01 (1.00-1.02) 1.00 (0.99-1.02) 0.48 0.0 (0.0-5.0) 0.99 (0.98-1.01) 0.99 (0.98-1.00) 1.00 (0.98-1.02) 0.28 0.001
Phenolic acid subclasses 508.2 (122.8-1317.8) 1.03 (0.99-1.08) 1.00 (0.95-1.05) 1.10 (1.02-1.19)* 0.038 561.9 (162.1-1395.7) 0.96 (0.91-1.01) 0.91 (0.85-0.97)** 1.04 (0.95-1.14) 0.015 0.001
Hydroxybenzoics 19.5 (1.3-155.0) 1.00 (0.98-1.03) 0.99 (0.96-1.02) 1.05 (1.00-1.10)* 0.03 23.0 (3.1-159.5) 1.00 (0.97-1.04) 1.00 (0.96-1.04) 1.01 (0.96-1.06) 0.93 0.10
Hydroxycinnamic 474.6 (95.5-1279.3) 1.02 (0.98-1.06) 1.01 (0.96-1.05) 1.07 (1.00-1.15)* 0.10 513.6 (118.2-1356.5) 0.96 (0.92-1.01) 0.92 (0.87-0.97)** 1.03 (0.96-1.11) 0.017 0.002
Hydroxyphenylacetic 0.1 (0.0-0.6) 0.99 (0.98-1.01) 0.99 (0.98-1.01) 1.00 (0.98-1.03) 0.54 0.2 (0.0-1.3) 1.00 (0.98-1.01) 0.99 (0.97-1.01) 0.98 (0.96-1.01) 0.12 0.40
Stilbenes 0.4 (0.0-6.6) 1.00 (0.98-1.01) 1.00 (0.98-1.02) 1.00 (0.97-1.03) 0.74 0.8 (0.0-11.8) 0.98 (0.96-0.99) 0.98 (0.96-1.00) 0.97 (0.95-1.00) 0.70 0.042
Lignans 1.4 (0.7-4.9) 1.01 (0.94-1.08) 0.98 (0.90-1.06) 1.08 (0.95-1.21) 0.20 1.6 (0.8-5.3) 1.06 (0.98-1.15) 1.11 (1.01-1.22) 0.99 (0.86-1.13) 0.17 0.83
Other polyphenol classes
Alkylphenols 24.4 (2.0-80.1) 1.00 (0.97-1.03) 1.00 (0.97-1.04) 1.00 (0.95-1.06) 0.95 39.7 (2.3-113.5) 0.99 (0.96-1.02) 0.99 (0.95-1.02) 1.01 (0.95-1.06) 0.57 <0.001
Tyrosol 3.5 (0.3-30.2) 0.99 (0.97-1.00) 0.99 (0.97-1.01) 0.97 (0.94-1.00) 0.26 4.5 (0.4-49.8) 0.99 (0.97-1.01) 1.00 (0.97-1.02) 0.97 (0.94-1.00) 0.22 0.20
Alkymethoxyphenols 2.2 (0.1-6.2) 1.01 (0.99-1.02) 1.00 (0.98-1.02) 1.04 (1.00-1.08)* 0.036 2.7 (0.3-7.3) 0.99 (0.98-1.01) 0.99 (0.97-1.01) 1.00 (0.97-1.03) 0.49 0.005
Furanocoumarins 0.0 (0.0-0.4) 1.00 (0.99-1.00) 1.00 (0.99-1.01) 0.99 (0.98-1.00) 0.39 0.0 (0.0-0.3) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 1.01 (0.99-1.02) 0.31 0.87
Hydroxybenzaldehydes 0.1 (0.0-1.5) 0.99 (0.98-1.01) 0.99 (0.98-1.01) 1.01 (0.98-1.03) 0.39 0.3 (0.0-2.5) 0.99 (0.98-1.01) 0.98 (0.96-1.00) 0.97 (0.95-1.00)* 0.10 0.008
Hydroxycoumarins 0.0 (0.0-0.4) 0.99 (0.99-1.00) 1.00 (0.99-1.01) 0.99 (0.98-1.01) 0.42 0.2 (0.0-1.3) 1.00 (0.99-1.01) 0.99 (0.98-1.01) 0.99 (0.98-1.00) 0.13 0.003
Hydroxyphenylpropenes 0.0 (0.0-4.0) 1.00 (1.00-1.01) 1.00 (1.00-1.01) 1.00 (0.99-1.01) 0.59 0.2 (0.0-5.8) 1.00 (1.00-1.01) 1.01 (1.00-1.01) 1.00 (0.99-1.01) 0.22 0.18
Methoxyphenols 0.3 (0.0-0.8) 1.01  (1.00-1.02) 1.00 (0.99-1.01) 1.02 (1.00-1.03)* 0.17 0.3 (0.0-0.8) 0.99 (0.98-1.00) 0.99 (0.98-1.00)** 0.99 (0.98-1.00) 0.73 <0.001
P-value2
MenWomen
P-value1 P-value1
Table 3 Click here to download table Table 3.docx 
Cox model was stratified by age and centre, and additionally adjusted for smoking status and intensity, physical activity, education 
level, body mass index, total energy intake, alcohol, red and processed meat, fibre (g/d) and calcium (mg/d) intakes and in women 
also for menopausal status , hormone replacement therapy use, and oral contraceptive use 
 
